Type2 Diabetes
Pipeline by Development Stage
Drug Modality Breakdown
Metabolic Diseases is a $70.5B mature market dominated by diabetes and anticoagulation therapies with sustained blockbuster momentum.
Key Trends
- GLP-1 agonists (Ozempic, Mounjaro) driving explosive growth and market consolidation
- SGLT2 inhibitors expanding beyond diabetes into cardio-renal indications
- Significant patent cliff risk 2027-2029 for DPP-4 inhibitors (Januvia) and older insulins
Career Verdict
Excellent opportunity for specialists seeking stable, high-revenue exposure with strong hiring momentum in commercial and engineering roles.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | ELIQUIS (apixaban) | Bristol Myers Squibb | $18.3B | 26% | Launch | Stable | 15.0yr |
| 2 | OZEMPIC (semaglutide) | Novo Nordisk | $9.2B | 13% | Peak | Growing | 12.4yr |
| 3 | JARDIANCE (empagliflozin) | Boehringer Ingelheim | $8.8B | 12% | Peak | Growing | 8.6yr |
| 4 | TRULICITY (dulaglutide) | Eli Lilly and Company | $7.4B | 10% | Peak | Stable | |
| 5 | FARXIGA (dapagliflozin) | AstraZeneca | $4.3B | 6% | Peak | Growing | 15.4yr |
Drug Class Breakdown
stable, mature franchise
rapid growth, expanding indications
growing, cardio-renal expansion
stable, generics pressure
declining, patent cliff 2027
Career Outlook
GrowingMetabolic diseases offers stable, high-value career trajectory with blockbuster product revenue supporting competitive compensation and long-term job security. Commercial and field-based roles dominate hiring, reflecting the shift toward patient access, digital health, and device integration in diabetes management. Patent cliff exposure in DPP-4 class (2027-2029) creates near-term volatility for Merck but limited impact on overall market given GLP-1 dominance.
Breaking In
Target device companies (Insulet, Abbott) or diagnostic firms for entry-level roles if traditional pharma hiring is limited; strong foundation in diabetes biology and HbA1c/CGM metrics will accelerate credibility.
For Experienced Professionals
Experienced professionals should prioritize GLP-1 franchise or SGLT2 indication expansion roles; avoid Merck DPP-4-focused assignments given 2027 patent cliff, unless willing to transition to next-generation pipeline.
In-Demand Skills
Best For
Hiring Landscape
Hiring activity is concentrated in commercial roles (166 positions) and engineering (126 positions), driven by device makers (Insulet: 270 jobs) and diagnostic companies (Abbott: 154 jobs) rather than traditional pharma. Sanofi leads pharma hiring with 42 metabolic-focused positions, but specialized roles in clinical operations remain constrained. Salary expectations range from $153K (Clinical Ops) to $274K (Manufacturing), with strong compensation for commercial and quality roles.
Top Hiring Companies
By Department
Strongest hiring momentum in device/delivery and commercial infrastructure; traditional pharma R&D roles remain limited despite blockbuster pipeline.
On Market (2)
Approved therapies currently available
Competitive Landscape
27 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 37 trials with date data
Clinical Trials (37)
Total enrollment: 10,765 patients across 37 trials
Approaches To Therapy Escalation In T2D
Effect of Dapagliflozin on Nighttime Blood Pressure in Type 2 Diabetes
Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases
Liraglutide Effects on Epicardial Fat Inflammatory Genes
Randomised Open Label Study of Insulin Degludec Versus Insulin Glargine U100 in Ramadan
Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)
GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes
Phase IV Clinical Trial to Investigate the Effect on Blood Glucose of Evogliptin in Patients With Type 2 Diabetes(EVERGREEN)
A Study of MSDC-0602K to Assess Glycemic Control and Cardiovascular Outcomes in Patients With Pre-T2D or T2D and NAFLD/NASH
A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both
Use of an Investigational Digital Therapeutic in Patients With Type 2 Diabetes
Efficacy and Safety of Evogliptin When Added to Ongoing Metformin and Dapagliflozin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control
Effect of Ertugliflozin on Cardiac Function in Diabetes
Effect of Alirocumab on Postprandial Hyperlipemia in Patients With Type 2 Diabetes
The Efficacy and Safety of CKD-501 Added to D150 Plus D759 Therapy in Patients With Type 2 Diabetes
Efficacy and Safety of CKD-501 Added to D150 Plus D745 25mg Therapy in Patients With Type 2 Diabetes
Efficacy and Safety of CKD-501 Added to D150 Plus D745 10mg Therapy in Patients With Type 2 Diabetes
Evaluate Safety as Mono or Combination Therapies With Anti-diabetes Mellitus Drugs in Japanese Subjects With Type 2 Diabetes Mellitus
A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
A Study With NLY01 in Subjects With Type 2 Diabetes
A Study to Evaluate the Effect of BioK+ 50B® on Glycemic Control in a Type 2 Diabetes Population
A Study to Investigate the Bioequivalence Test of DA-1229_01(A) at Fed State
A Study to Investigate the Bioequivalence Test of DA-1229_01(A) at Fasting State
Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Evogliptin and Empagliflozin or Dapagliflozin in Healthy Male Adults
Stem Cells From Human Exfoliated Teeth in Treatment of Type 2 Diabetes
Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Evogliptin 5mg and Glimepiride 4mg
OP5-005 Using Omnipod 5 in Adults With Type 2
Novel Organic Kale Products for Prevention of Obesity/Type 2 Diabetes
Diabetes Pueblo Program - Application and Acceptability of Culturally Appropriate Latino Education for Insulin Therapy
Effects of White Potato Consumption on Measures of Cardiometabolic Health in Individuals With Type 2 Diabetes Mellitus
Peer Support To Enhance The Shanghai Integration Model Of Diabetes Care: Dissemination To 12 Communities
Retrospective Study to Evaluate the Safety of Duvie in Korean Patients With Type 2 Diabetes Mellitus
Depression & Insulin Sensitivity in Adolescents
Experimental Changes in Children's Sleep Duration and Timing: Effect on Obesity and Type 2 Diabetes Risk
Using Multifamily Groups to Improve Self-Management of Type 2 Diabetes
Evaluation of Type 2 Diabetes Treatment
Accuracy Characterization Study
Related Jobs in Metabolic Diseases
Manager, GxP Quality Systems
Director, Global Medical Affairs - Rare Metabolic Disorders
3PL Operations Manager
Scientist, Drug Product Analytical
Medical Director, Pharmacovigilance
Manager, Drug Product
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.